Diogo Belo
Nephrology · Chula Vista, CANPI 1326043027
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,335 of the $5,032 with a category attached, or 66.3%. 25 manufacturers reported payments, led by Novo Nordisk AS at 55.4% of the total. Reporting peaked in 2019 at $4,594 and has fallen 92.9% since, to $328 in 2022.
Across 92 payments — averaging $54.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$3K
- Otsuka America Pharmaceutical, Inc.$368
- Amgen$251
- AstraZeneca$187
- Mallinckrodt Enterprises LLC$174
- Akebia Therapeutics Inc$169
- plus $1K from 19 others
Across 294 payments — averaging $3768.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$493K
- Bayer$328K
- Akebia Therapeutics Inc$134K
- Sanofi US Services Inc.$53K
- AbbVie$35K
- Gilead$35K
- plus $30K from 3 others
What the payments were for
- Travel & lodging$1,48630%
- Food & beverage$3,33566%
- Education$2114%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 14 | $2,787 |
| Otsuka America Pharmaceutical, Inc. | 14 | $368 |
| Amgen(2 entities) | 6 | $251 |
| AstraZeneca(2 entities) | 4 | $187 |
| Mallinckrodt Enterprises LLC | 8 | $174 |
| Akebia Therapeutics Inc | 6 | $169 |
| Lilly USA, LLC | 8 | $138 |
| Amarin Pharma, Inc. | 3 | $125 |
| Sanofi | 1 | $123 |
| OPKO Pharmaceuticals, LLC | 6 | $118 |
| Nxstage Medical, Inc. | 1 | $107 |
| Gilead | 1 | $96 |
| Shire North American Group Inc | 5 | $91 |
| Vifor Pharma, Inc. | 2 | $44 |
| Fresenius USA Marketing, Inc. | 2 | $38 |
| Daiichi Sankyo Inc. | 2 | $38 |
| GSK | 1 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| AMAG Pharmaceuticals, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Merck | 1 | $17 |
| Cumberland Pharmaceuticals, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$125
- FABRAZYME$123
- CARTRIDGES$107
- FLUIDS$107
- PURE FLOW$107
- System One$107
How this compares
$5,032 in reported general payments places this provider in the 75th percentile of 1,341 nephrology providers in California.
Other nephrology in Chula Vista
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.